{"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"62"}],"units":"Participants"}],"groups":[{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 30-60 minutes on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"BG000","title":"Group1_Dose 1 200mgm2"},{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 30-60 minutes on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"BG001","title":"Group 1_Dose 2 225mgm2"},{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 8-9 hours on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"BG002","title":"Group 2_Dose 1 200mgm2"},{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 8-9 hours on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"BG003","title":"Group 2_Dose 225mgm2"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"22"},{"groupId":"BG004","value":"47"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"15"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"22"},{"groupId":"BG004","value":"42"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"9"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"23"},{"groupId":"BG004","value":"53"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"62"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}